Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics

Core Viewpoint - Analysts forecast Regeneron (REGN) will report quarterly earnings of $8.03 per share, reflecting a year-over-year decline of 30.5%, with anticipated revenues of $3.34 billion, a decrease of 5.7% compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 6.5% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Forecasts - Analysts predict 'Revenues- Other Revenue' at $125.38 million, a year-over-year increase of 20% [5]. - 'Revenues- Net product sales' are expected to reach $1.46 billion, reflecting a decline of 23.9% year-over-year [5]. - 'Total Bayer collaboration revenue' is projected at $388.54 million, indicating a year-over-year increase of 3.6% [5]. - The consensus estimate for 'Revenues- Collaboration' stands at $1.73 billion, a year-over-year increase of 13.7% [6]. - 'Revenues- Eylea (Aflibercept)- US' are expected to be $1.03 billion, down 33% from the prior year [6]. - 'Revenues- Praluent (alirocumab)- US' are forecasted at $54.57 million, a decrease of 2.7% year-over-year [6]. Product-Specific Revenue Insights - 'Revenues- Libtayo- US' are estimated to reach $234.04 million, reflecting a year-over-year increase of 28.3% [7]. - 'Revenues- Evkeeza- US' are expected at $36.84 million, indicating an 18.8% year-over-year increase [7]. - 'Revenues- Dupixent (dupilumab)- ROW' are projected at $1.16 billion, a year-over-year increase of 22.7% [8]. - 'Revenues- Dupixent (dupilumab)- US' are expected to reach $3.05 billion, reflecting a year-over-year increase of 16.7% [8]. - 'Revenues- Kevzara (sarilumab)- ROW' are estimated at $47.83 million, indicating a year-over-year increase of 7.2% [9]. Market Performance - Over the past month, shares of Regeneron have returned +6.4%, outperforming the Zacks S&P 500 composite's +3.6% change [9].